IL148968A0 - Neutral-cationic lipid for nucleic acid and drug delivery - Google Patents

Neutral-cationic lipid for nucleic acid and drug delivery

Info

Publication number
IL148968A0
IL148968A0 IL14896800A IL14896800A IL148968A0 IL 148968 A0 IL148968 A0 IL 148968A0 IL 14896800 A IL14896800 A IL 14896800A IL 14896800 A IL14896800 A IL 14896800A IL 148968 A0 IL148968 A0 IL 148968A0
Authority
IL
Israel
Prior art keywords
neutral
nucleic acid
drug delivery
cationic lipid
sup
Prior art date
Application number
IL14896800A
Other languages
English (en)
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of IL148968A0 publication Critical patent/IL148968A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL14896800A 1999-10-08 2000-10-10 Neutral-cationic lipid for nucleic acid and drug delivery IL148968A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15869399P 1999-10-08 1999-10-08
PCT/US2000/027974 WO2001026629A2 (en) 1999-10-08 2000-10-10 Neutral-cationic lipid for nucleic acid and drug delivery

Publications (1)

Publication Number Publication Date
IL148968A0 true IL148968A0 (en) 2002-11-10

Family

ID=22569279

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14896800A IL148968A0 (en) 1999-10-08 2000-10-10 Neutral-cationic lipid for nucleic acid and drug delivery

Country Status (17)

Country Link
US (2) US6974589B1 (xx)
EP (1) EP1223916B1 (xx)
JP (1) JP2003511405A (xx)
KR (1) KR100723852B1 (xx)
CN (2) CN1915968A (xx)
AT (1) ATE276744T1 (xx)
AU (2) AU7868400A (xx)
CA (1) CA2386164A1 (xx)
DE (1) DE60014133T2 (xx)
DK (1) DK1223916T3 (xx)
ES (1) ES2226932T3 (xx)
HU (1) HUP0203117A3 (xx)
IL (1) IL148968A0 (xx)
MX (1) MXPA02002899A (xx)
NO (1) NO20021615D0 (xx)
WO (2) WO2001026625A2 (xx)
ZA (1) ZA200202726B (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7238368B2 (en) 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
AU769425B2 (en) 1999-04-23 2004-01-29 Alza Corporation Conjugate having a cleavable linkage for use in a liposome
US7303760B2 (en) 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
US20040197390A1 (en) * 2001-05-29 2004-10-07 Shi-Kun Huang Neutral-cationic lipid for systemic delivery of factor VIII gene
WO2001026625A2 (en) 1999-10-08 2001-04-19 Alza Corp Neutral-cationic lipid for nucleic acid and drug delivery
DE10207177A1 (de) * 2002-02-19 2003-09-04 Novosom Ag Fakultativ kationische Lipide
CN102940891B (zh) * 2004-05-05 2016-02-24 赛伦斯治疗有限公司 脂质、脂质复合物及其应用
EP1935434A1 (en) * 2006-12-19 2008-06-25 Novosom AG Construction and use of transfection enhancer elements
MX2009011320A (es) 2007-04-20 2009-12-15 Enzon Pharmaceuticals Inc Terapia anticancer enzimatica.
CN101475503B (zh) * 2008-12-15 2012-02-15 山东大学 一种新型阳离子类脂及其制备方法和应用
EP2532649B1 (en) * 2011-06-07 2015-04-08 Incella GmbH Amino lipids, their synthesis and uses thereof
IL280771B2 (en) 2011-06-08 2024-03-01 Shire Human Genetic Therapies Preparations of lipid nanoparticles and methods for administration of mRNA
WO2013151326A1 (en) * 2012-04-04 2013-10-10 Samyang Biopharmaceuticals Corporation Method of preparing composition for delivering an anionic drug
CN105585598B (zh) * 2014-10-20 2019-02-19 湖南师范大学 甘露糖衍生物阳离子脂质体纳米颗粒的制备方法
BR112018007611A2 (pt) * 2015-10-14 2018-10-23 Bio Path Holding Inc ácidos nucleicos p-etóxi para formulação lipossômica
CN107200841B (zh) * 2016-03-17 2019-02-01 华东师范大学 一种培化二酰甘油的合成方法
CN110709065B (zh) * 2017-04-19 2023-02-10 Apa先进技术有限公司 融合脂质体、组合物、试剂盒及其治疗癌症的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5965434A (en) * 1994-12-29 1999-10-12 Wolff; Jon A. Amphipathic PH sensitive compounds and delivery systems for delivering biologically active compounds
DE19521412A1 (de) * 1995-06-14 1996-12-19 Boehringer Mannheim Gmbh Neue kationische und polykationische Amphiphile, diese enthaltende Reagenzien und deren Verwendung
US5855911A (en) 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
TW520297B (en) * 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
WO2000030444A1 (en) 1998-11-25 2000-06-02 Vanderbilt University Cationic liposomes for gene transfer
WO2001026625A2 (en) 1999-10-08 2001-04-19 Alza Corp Neutral-cationic lipid for nucleic acid and drug delivery

Also Published As

Publication number Publication date
EP1223916A2 (en) 2002-07-24
AU7868400A (en) 2001-04-23
DE60014133T2 (de) 2005-02-03
CN1378536A (zh) 2002-11-06
WO2001026629A3 (en) 2002-05-10
JP2003511405A (ja) 2003-03-25
WO2001026625A2 (en) 2001-04-19
EP1223916B1 (en) 2004-09-22
ZA200202726B (en) 2003-06-25
KR20020063875A (ko) 2002-08-05
AU778817B2 (en) 2004-12-23
NO20021615L (no) 2002-04-05
MXPA02002899A (es) 2002-10-23
AU8006400A (en) 2001-04-23
US20050260261A1 (en) 2005-11-24
DE60014133D1 (de) 2004-10-28
HUP0203117A2 (hu) 2003-01-28
US6974589B1 (en) 2005-12-13
ATE276744T1 (de) 2004-10-15
ES2226932T3 (es) 2005-04-01
HUP0203117A3 (en) 2005-06-28
DK1223916T3 (da) 2005-01-31
CN1915968A (zh) 2007-02-21
NO20021615D0 (no) 2002-04-05
KR100723852B1 (ko) 2007-05-31
WO2001026629A2 (en) 2001-04-19
CA2386164A1 (en) 2001-04-19

Similar Documents

Publication Publication Date Title
IL148968A0 (en) Neutral-cationic lipid for nucleic acid and drug delivery
IL110091A (en) POLYSUBSTITUTED IMIDAZO £4, 5-c| PYRIDIN-4-AMINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
ATE178067T1 (de) Camptothecinderivate
HK1069285A1 (en) Improved synthesis of polyanhyrides
WO1999020639A3 (en) NOVEL 3,6-HEMIKETALS FROM THE CLASS OF 9a-AZALIDES
GR3020682T3 (en) Use of dioxabicyclo [3.3.0]octane derivatives for the manufacture of a medicament for inhibiting the metabolism of cholesterol.
WO2002007677A3 (en) Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder
NZ521201A (en) Method for the preparation of citalopram
EP0335979A4 (en) Thienopyrimidine derivatives
WO2003051848A3 (en) Imidazolidineacetic acid derivatives
ATE477263T1 (de) Zusammensetzung enthaltend ferrocen-derivate und treibstoff diese enthaltend
EP1028721A4 (en) N, N'-BIS (SULFONYL) HYDRAZINES FOR USE AS ANTINEOPLASTIC AGENTS
ZA200101619B (en) Process for the preparation of substituted amido phthalocyanine derivatives and substituted amido phthalocyanine derivatives.
WO2003075928A3 (en) Stable pharmaceutical compositions
PL322069A1 (en) Arginin analoques exhibiting inhibiting activity in respect to synthase no
EP0204148A3 (en) [1,4]Benzodioxin and [1,4]benzoxazine derivatives
AU3181600A (en) 2'-substituted rna preparation
HK1049152A1 (en) 1,4-dihydropyridine-5-carboxylic acid ester derivatives and method for the preparation thereof
CA2338776A1 (en) Novel c-2 s/o- and s/n formaldehyde acetal derivatives of carbapenem-3-carboxylic acids and their use as antibiotics and .beta.-lactamase inhibitors
GB2321459A (en) Synthesis of carboxylic acid derivatives
IL106080A (en) Pharmaceutical compositions containing amidinoalkane-1, 1-bisphosphonic acids and some such novel compounds
IT1276161B1 (it) Derivati dell'acido fosfonico ad attivita' inibitrice delle metallopeptidasi
NZ524330A (en) Substituted biphenyl derivatives, method for preparing same and pharmaceutical compositions containing same